Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Onco-Innovations Ltd. ( (TSE:ONCO) ) has provided an announcement.
Onco-Innovations’ subsidiary, Inka Health, has published a technical primer on the transportability of real-world evidence (RWE) in the Journal of Clinical Evaluative Research. This publication, co-authored with AstraZeneca Canada, addresses the challenge of adapting medical evidence across borders, which can accelerate regulatory approvals and improve patient access to innovative therapies, especially in rare diseases. The primer outlines principles and statistical techniques for reliable cross-border evidence sharing, which will be integrated into Inka Health’s SynoGraph platform. This advancement supports more precise and evidence-based treatment decisions worldwide, breaking down geographic barriers in oncology research and potentially speeding up the delivery of life-saving treatments.
More about Onco-Innovations Ltd.
Onco-Innovations Limited is a Canadian-based company specializing in oncology research and treatment. The company focuses on the prevention and treatment of cancer through pioneering research and innovative solutions, holding an exclusive worldwide license to patented technology targeting solid tumors. Its subsidiary, Inka Health, is an AI-driven analytics company that revolutionizes oncology research and drug development through its proprietary platform, SynoGraph, which leverages AI-powered causal inference to advance precision medicine.
Average Trading Volume: 39,051
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$79.79M
For an in-depth examination of ONCO stock, go to TipRanks’ Overview page.